A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms
Latest Information Update: 27 Jan 2022
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Eprenetapopt (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders; Tumours
- Focus Adverse reactions; Therapeutic Use
- 14 Jan 2022 Status changed from active, no longer recruiting to completed.
- 03 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 14 Dec 2021 Results of long-term follow up analyses of two studies (NCT03072043/NCT03588078) presented at the 63rd American Society of Hematology Annual Meeting and Exposition.